

Bibliographie

1. Kunkel, T. A. Celebrating DNA's Repair Crew. *Cell* **163**, 1301–3 (2015).
2. Abegglen, L. M. *et al.* Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans. *JAMA* **314**, 1850–60 (2015).
3. Krug, N. *et al.* Allergen-induced asthmatic responses modified by a GATA3-specific DNase. *N. Engl. J. Med.* **372**, 1987–95 (2015).
4. Bel, E. H. *et al.* Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N. Engl. J. Med.* **371**, 1189–97 (2014).
5. Brusselle, G. G., Bracke, K. & Lahousse, L. Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts. *Lancet. Respir. Med.* **3**, 416–7 (2015).
6. Martinez, F. J. *et al.* Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. *Lancet (London, England)* **385**, 857–66 (2015).
7. Brahmer, J. *et al.* Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* **373**, 123–35 (2015).
8. Jänne, P. A. *et al.* AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N. Engl. J. Med.* **372**, 1689–99 (2015).
9. Cowie, M. R. *et al.* Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. *N. Engl. J. Med.* **373**, 1095–105 (2015).
10. Couzin-Frankel, J. Cancer Immunotherapy. *Science (80-.)*. **342**, 1432–1433 (2013).
11. Ansell, S. M. *et al.* PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N. Engl. J. Med.* **372**, 311–9 (2015).
12. Burger, J. A. *et al.* Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. *N. Engl. J. Med.* **373**, 2425–37 (2015).
13. Chanan-Khan, A. *et al.* Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. *Lancet. Oncol.* (2015). doi:10.1016/S1470-2045(15)00465-9
14. Muehlenbachs, A. *et al.* Malignant Transformation of *Hymenolepis nana* in a Human Host. *N. Engl. J. Med.* **373**, 1845–52 (2015).
15. Cannon, C. P. *et al.* Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N. Engl. J. Med.* **372**, 2387–97 (2015).
16. Robinson, J. G. *et al.* Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N. Engl. J. Med.* **372**, 1489–99 (2015).
17. Clark, N. P. *et al.* Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures. *JAMA Intern. Med.* **175**, 1163–8 (2015).
18. Douketis, J. D. *et al.* Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. *N. Engl. J. Med.* **373**, 823–33 (2015).
19. Feldman, T. *et al.* Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation. *J. Am. Coll. Cardiol.* **66**, 2844–2854 (2015).
20. Maisano, F. *et al.* Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. *Eur. Heart J.* (2015). doi:10.1093/eurheartj/ehv603
21. Reynolds, D. *et al.* A Leadless Intracardiac Transcatheter Pacing System. *N. Engl. J. Med.* **374**, 533–41 (2016).
22. Kapadia, S. R. *et al.* 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet (London, England)* **385**,

- 2485–91 (2015).
23. Thyregod, H. G. H. *et al.* Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial. *J. Am. Coll. Cardiol.* **65**, 2184–94 (2015).
 24. Langley, R. G. *et al.* Secukinumab in plaque psoriasis--results of two phase 3 trials. *N. Engl. J. Med.* **371**, 326–38 (2014).
 25. Thaçi, D. *et al.* Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. *J. Am. Acad. Dermatol.* **73**, 400–9 (2015).
 26. Mease, P. J. *et al.* Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. *N. Engl. J. Med.* **373**, 1329–39 (2015).
 27. McInnes, I. B. *et al.* Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet (London, England)* **386**, 1137–46 (2015).
 28. Kavanaugh, A. *et al.* Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. *J. Rheumatol.* **42**, 479–88 (2015).
 29. Bannister, C. A. *et al.* Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. *Diabetes, Obes. Metab.* **16**, 1165–1173 (2014).
 30. Vlotides, G. & Mertens, P. R. Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease. *Nephrol. Dial. Transplant* **30**, 1272–6 (2015).
 31. Zinman, B. *et al.* Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N. Engl. J. Med.* **373**, 2117–28 (2015).
 32. von Hurst, P. R., Stonehouse, W. & Coad, J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient – a randomised, placebo-controlled trial. *Br. J. Nutr.* **103**, 549–555 (2010).
 33. Talaei, A., Mohamadi, M. & Adgi, Z. The effect of vitamin D on insulin resistance in patients with type 2 diabetes. *Diabetol. Metab. Syndr.* **5**, 1–5 (2013).
 34. Zhu, Y. *et al.* High uric acid directly inhibits insulin signalling and induces insulin resistance. *Biochem. Biophys. Res. Commun.* **447**, 707–714 (2014).
 35. Williams, B. *et al.* Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. *Lancet (London, England)* **386**, 2059–68 (2015).
 36. Kümpers, P. [NaCl 0.9 % for volume substitution : blessing or curse?]. *Internist (Berl.)* **56**, 773–8 (2015).
 37. Rauen, T. *et al.* Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. *N. Engl. J. Med.* **373**, 2225–36 (2015).